European shares closed higher on Thursday, after a business activity index showed the euro zone rebounded in July.» Read More
Hal Barron, Roche/Genentech chief medical officer, shares several new developments in treating cancer, including some promising results with Roche/Genentech 's Avastin.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.
European shares were higher in early afternoon trade on Wednesday despite preliminary growth data from the euro zone missing estimates.
European shares closed sharply higher on Tuesday after a positive Spanish bond auction and better-than-expected French manufacturing data buoyed investor sentiment.
Genetic testing equipment maker Life Technologies has agreed to a $13.6 billion cash buyout by Thermo Fisher Scientific, in one of the year's biggest corporate takeovers.
European shares closed higher on Thursday after better-than-expected initial jobless claims data from the U.S. The numbers are important as a key metric for Fed policy makers, who have said they could taper off asset purchases once the labor market improves.
Daniel O'Day, head of pharmaceutical operations at Roche, tells CNBC that the company haven't seen a huge effect from the Sequester in the US.
Andrew Weiss, head of Pharma at Vontobel, tells CNBC that Roche delivered earnings in line with expectations.
China said it was mobilizing resources nationwide to combat a new strain of bird flu that has killed six people, as Japan, Hong Kong and the United States stepped up vigilance.
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
China has found two more cases of a new strain of bird flu and one of the victims has died, bringing to nine the number of confirmed human infections from the previously unknown flu type.
India's top court has dealt a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
Share price may already seem high but Jim Cramer thinks it deserves to be even higher.
Facebook appointed a former Genentech executive to its board of directors, the social networking company's latest move to expand its boardroom following its initial public offering last May.
Swiss citizens voted on Sunday to impose some of the world's strictest controls on executive pay, forcing public companies to give shareholders a binding vote on compensation, result projections showed.
European shares suffered their biggest daily drop this month after gloomy earnings and weak U.S. economic data hit sentiment on Wednesday and left some positioning for further falls in the near-term.
U.S. stock index futures pointed to a slightly higher open on Wednesday, with eyes on the Federal Reserve’s first policy statement of 2013.
Severin Schwan, CEO of Roche, tells CNBC that 2012 was a very good year for Roche with the company outgrowing their markets in both Pharma and Diagnostics by five and four percent.
TheStreet.com offers up 13 biotech predictions for 2013.
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.